Bench top to IPO: The story of Alan Taylor, Clarity Pharmaceuticals

​From Australian benchtop science to the largest ever biotech IPO on the ASX, hear the story of how Dr Alan Taylor steered Clarity Pharmaceuticals to become a global leader in radiopharmaceuticals.

​Cicada Innovations has a twenty-one year track record of supporting deep tech ventures along their journey of solving some of the world’s most pressing problems. Everyday we are fortunate to work with incredibly talented, passionate, and driven people who believe in a better future for people, planet, and prosperity.

​Dr Alan Taylor and the team at Clarify Pharmaceuticals personify this. Clarity has been a resident at Cicada for 10 years, and Alan has grown the team and business from two provisional patents and no full time employees, to a global leader in radiopharmaceuticals within our four walls. 

​Last year, Clarity was successful in completing the largest ever life sciences listing on the ASX. Because of lockdowns we didn’t get to properly celebrate this momentous achievement, and so we will be sitting down with Dr Alan Taylor to discuss what it took to reach this incredible milestone.

​Alan has been instrumental in the growth of Clarity, being heavily involved in every facet of the business, including leading over $130 million in capital raisings. Prior to joining Clarity, he spent 15 years in investment banking, advising numerous companies in the healthcare, life sciences and technology areas and executing on capital raisings, and mergers & acquisitions amounting to approx. $2 billion worth of transactions, including the largest life sciences IPOs on the ASX prior to Clarity’s listing. Alan also holds a PhD in Medicine from the Garvan Institute of Medical Research.

​For our March Cicada Buzz,  Alan will share Clarity’s journey, his advice for entrepreneurs on steering a company from idea to IPO and his vision for the future of the Australian health and life sciences ecosystem.